Legal Implications for Physicians Recommending Medical Cannabis in the USA
In our studies examining the use of Medical Cannabis Therapy (MCT) by Oncologists and Pain Management Specialists, we asked physicians what their biggest barrier was to their adoption of medical cannabis.  Two-thirds (65%), mention legal concerns. Concern for legal exposure and increased risk of malpractice associated with MCT remains... Read more
From the Cannabis Diaries: Mind the Technology Gap
By Matt Leathers Cannabis industry watchers assume that when the giants start moving aggressively,the changes will be seismic. Private equity and venture capital are moving into the space, along with internal M&A teams. Smaller providers will need to grow and scale without losing their focus on quality. As the regulatory fog... Read more
Another marijuana company is paying big to get in on the Illinois market. Chicago-based Grassroots Cannabis to be sold for $875 million.
Grassroots Cannabis is set to be acquired for $875 million, becoming the latest Chicago-based marijuana company to draw a blockbuster price tag from an out-of-state operator. Curaleaf Holdings, based in Massachusetts, announced Wednesday morning its plan to acquire Grassroots. The acquisition will allow Curaleaf to expand its presence into... Read more
Laval, Québec, CANADA – July 18, 2019 – PRESS RELEASE – Neptune Wellness Solutions Inc., a North American cannabinoids extraction, formulation and packaging company, has completed a private placement with both existing and new institutional investors, led by Perceptive Advisors, resulting in gross proceeds to the company of US$41.4 million.... Read more
Laval, Québec, CANADA – July 18, 2019 – PRESS RELEASE – Neptune Wellness Solutions Inc., a North American cannabinoids extraction, formulation and packaging company, has completed a private placement with both existing and new institutional investors, led by Perceptive Advisors, resulting in gross proceeds to the company of US$41.4 million.... Read more
The Food and Drug Administration has begun developing regulatory guidance on CBD, and commissioners have invited the public to weigh in on how to proceed. A public comment period closed this week, providing the FDA with nearly 3,500 perspectives on the legality, availability and apparent health benefits of CBD... Read more
The Food and Drug Administration has begun developing regulatory guidance on CBD, and commissioners have invited the public to weigh in on how to proceed. A public comment period closed this week, providing the FDA with nearly 3,500 perspectives on the legality, availability and apparent health benefits of CBD... Read more
The Food and Drug Administration has begun developing regulatory guidance on CBD, and commissioners have invited the public to weigh in on how to proceed. A public comment period closed this week, providing the FDA with nearly 3,500 perspectives on the legality, availability and apparent health benefits of CBD... Read more
Pot Stocks to Watch as We Enter The Second Half of Summer 

The marijuana stock market has grown drastically over the course of the past few years. In that time, we have seen company values skyrocket. Additionally, we have seen the amount of investor faith in the pot stock space grow as well. All of this has led to one of the friendliest investor spaces we have […]

The post Pot Stocks to Watch as We Enter The Second Half of Summer  appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Read more
Is Investing in Marijuana Stocks the Right Choice?

Marijuana Stocks

Marijuana stocks have very quickly become one of the most popular aspects of the stock market. With so much value and so many willing to participate, it looks as though cannabis is the way of the future. The increasing amount of people buying cannabis stocks has helped to bring a large amount of attention into […]

The post Is Investing in Marijuana Stocks the Right Choice? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )